The Readout Loud 351: It's gonna be May (in biotech)
9 snips
May 1, 2025 Join Gideon Gil, Managing Editor at STAT, and Zach Tracer, Senior Editor at STAT, as they explore major shifts in the biotech landscape following the Trump administration's first 100 days. They delve into the recent resurgence of biotech mergers and acquisitions and highlight the impressive launches of new drugs. The discussion also touches on Eli Lilly's challenges regarding patient access and the competitive dynamics with Novo Nordisk. Humorously, they juxtapose industry insights with pop culture, featuring a nod to a Justin Timberlake meme.
AI Snips
Chapters
Transcript
Episode notes
NIH Funding Slump's Impact
- NIH grants approved dropped by $2.3 billion in Trump's first 100 days compared to previous years.
- Cuts and halted grant approvals have forced universities to freeze hiring and reduce PhD admissions.
Indirect Costs Are Essential
- Indirect research costs cover real expenses like lab upkeep and staff overseeing ethical compliance.
- Slashing funding to 15% would damage major research universities, especially in costly cities.
Congress Pushes Back on Cuts
- Congressional committees hold authority over NIH budgets and have resisted Trump's proposed research cuts.
- Researchers warn cuts threaten clinical trials and ongoing advances in key disease areas.